36 / 53
Peters, et al. N Engl J Med 2017
Cause-specific HR: 0.18 p<0.0001
31.5%
(95% CI: 22.1–41.3)
4.6%
(95% CI: 1.5–10.6)
Cumulative incidence (%)
100
80
60
40
20
0
0
24
18
12
6
Time (months)
Alectinib (n=88)
Crizotinib (n=93)
Cumulative incidence of CNS progression
without CNS metastases
at baseline
with CNS metastases
at baseline
58.3%
(95% CI: 43.4–70.5)
16.0%
(95% CI: 8.2–26.2)
100
80
60
40
20
0
0
24
18
12
6
Time (months)
Alectinib (n=64)
Crizotinib (n=58)
Cause-specific HR: 0.14 p<0.0001